This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: September 15th, 2009 - September 15th, 2010
This activity is no longer available for credit, however its content is still relevant for your educational needs.
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.
At the completion of this activity participants should be able to:
- Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving breast cancer treatment that providers are using as the basis for their treatment decisions
- Offer payers a multistakeholder commentary on this information, to identify the impact on different stakeholders of these changes to treatment
- Illuminate the different perspectives and incentives of the various stakeholders involved in breast cancer treatment decisions: patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
- Align incentives with providers and transform payer drug management policies into patient-centered, value based models
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakerâ€™s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.
The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.
Dr Owens is a consultant to AstraZeneca, Genentech, and Wyeth, and is on the advisory board of ImClone Systems, Roche, and sanofi-aventis.
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.
*Content will include non-FDA-approved uses.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.